After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Frequent outbreaks of coronaviruses underscore the need for antivirals and vaccines that
can counter a broad range of coronavirus types. We isolated a human antibody named 76E1 …

A key barrier to the development of vaccines that induce broadly neutralizing antibodies
(bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic …

The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion.
Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

It is essential to acknowledge the efforts made thus far to manage or eliminate various
disease burden faced by humankind. However, the rising global trends of the so-called …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …